Literature DB >> 12510077

[Is sufficient femoral head coverage obtained after Pemberton's pericapsular osteotomy? Evaluation by three-dimensional computed tomographic reconstruction].

A Erdem Bagatur1, Gazi Zorer, Y Bilge Sürel.   

Abstract

OBJECTIVES: We evaluated femoral head coverage by three-dimensional computed tomographic reconstruction after Pemberton's pericapsular osteotomy with open reduction in cases with developmental dysplasia of the hip.
METHODS: In a prospective design, routine radiographs of 15 consecutive patients were obtained and three-dimensional computed tomographic reconstruction was performed preoperatively and six months after surgery. The mean age at the time of surgery was 26 months (range 18 to 34 months). Twelve patients were girls and three were boys.
RESULTS: The mean acetabular index was 38 degrees (range 33 degrees -52 degrees ) preoperatively, and 19 degrees (range 16 degrees -23 degrees ) postoperatively. Comparison between pre- and postoperative three-dimensional computed tomographic reconstruction images revealed increased acetabular adduction and extension, and decreased acetabular anteversion in all cases. Sufficient coverage of the femoral head was documented in all patients.
CONCLUSION: Pemberton's pericapsular osteotomy provides successful results in appropriate cases, with sufficient coverage of the femoral head. However, if there is any doubt, utilization of three-dimensional computed tomographic reconstruction images may contribute to a more precise evaluation of the outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12510077

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


  1 in total

1.  A Comparative Study of Salter Versus Pemberton Osteotomy in Open Reduction of Developmental Dysplastic Hips and Clinical Evaluation on Bhatti's Functional Score System.

Authors:  Anisuddin Bhatti; Imamuddin Abbasi; Zeehan Naeem; Kiran Jaffri; Muhammad Yousuf Bhatti
Journal:  Cureus       Date:  2021-01-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.